IP Verse

Methods Of Treating Antibody-Mediated Rejection In Organ Transplant Patients With C1-Esterase Inhibitor - EP3071219

The patent EP3071219 was granted to Shire Viropharma on Nov 14, 2018. The application was originally filed on Nov 21, 2014 under application number EP14809567A. The patent is currently recorded with a legal status of "Revoked".

EP3071219

SHIRE VIROPHARMA
Application Number
EP14809567A
Filing Date
Nov 21, 2014
Status
Revoked
Jan 8, 2025
Grant Date
Nov 14, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CSL INNOVATIONAug 14, 2019MEWBURN ELLISADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP1240904
INTERNATIONAL-SEARCH-REPORTWO2013041677
INTERNATIONAL-SEARCH-REPORTWO2014145519
OPPOSITIONEP1240904
OPPOSITIONWO2013041677
OPPOSITIONWO2014145519
OPPOSITIONWO2015077543

Non-Patent Literature (NPL) Citations (41) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant, (20190610), URL: https://clinicaltrials.gov/ct2/show/NCT02547220, (20190805), XP055633917-
OPPOSITION- A Randomized Double-Blind Placebo-Controlled Pilot Study to D1 Evaluate the Safety and Effect of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Recipients of Donor-Sensitized Kidney Transplants, (20131118), URL: https://clinicaltrials.gov/archive/NCT01147302/2013_ 11_ 18, (20150108), XP002734260-
OPPOSITION- "Berinert 500 IU, CSL Behring UK Package Leaflet: Information For The User", MHRA, (20120000), pages 1 - 6, XP055633929-
OPPOSITION- "Bioavailability", Bioavailability, (20121100), wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Bioavailability&oldid=525072 520, XP055635098-
OPPOSITION- "Blood volume", Blood, (20121100), wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Blood_volume&oldid=52189 4834, XP055635100-
OPPOSITION- BUERKE et al., "Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury", J Pharmacol Exp Ther., (19980000), vol. 286, pages 429 - 38, XP002987246-
OPPOSITION- "definition of ''small entity status", Extract from USPTO MPEP --
OPPOSITION- ELERT et al., "Volume of Blood in a Human", The Physics FactbookTM, (20060307), URL: https://web.archive.org/web/20060307062158/ https://hypertextbook.com/facts/1998/LanNaLee.shtml-
OPPOSITION- GARCES et al., "Antibody-Mediated Rejection: A Review", Ochsner Journal, (20170000), vol. 17, pages 46 - 55, XP055633941-
OPPOSITION- Half Life Calculator, (20120518), URL: https://web.archive.org/web/20120518064528 / http://www.calculator.net/ half -life-calculator. html-
OPPOSITION- Half Life Calculator, (20120726), URL: https://web.archive.org/web/20120726190637 / https://www.miniwebtooi. com/half-life-calculator-
OPPOSITION- MONTGOMERY et al., "Human Plasma-Derived C1 Esterase Inhibitor D2 for the Treatment of Acute Antibody Mediated Rejection in Kidney Transplantation", AMERICAN JOURNAL OF TRANSPLANTATION, (20140627), vol. 14, no. S3, pages 129 - 130, XP002734261-
OPPOSITION- MOSQUERA REBOREDO et al., "Diagnostic criteria of antibody- mediated rejection in kidney transplants", Nefrologia, (20110000), vol. 31, pages 382 - 391, XP055635127-
OPPOSITION- POIRIER et al., "Recombinant Human C1-Inhibitor Inhibits Cytotoxicity Induced by Allo- and Xenoantibodies", Transplantation Proceedings, (20080000), vol. 40, pages 581 - 583, XP022553420-
OPPOSITION- "Rate equation", Rate equation, (20121200), wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Rate_equation&oldid=52580 9327, XP055635092-
OPPOSITION- Recombinant Human C1 Inhibitor for the Treatment of Early Antibody D9 Mediated Rejection in Renal Transplantation, (20120215), URL: https://www.clinicaltrials.gov/ct2/show/NCT01035593?term=amr+c 1 &rank=2, (20150108), XP002734264-
OPPOSITION- REINHART et al., "septic shock", Sepsis. Current Perspectives in Pathophysiology and Therapy, Berlin Heidelberg, (19940000), pages 512 - 514, XP055635087-
OPPOSITION- ROWLAND et al., "chapter 3", CLINICAL PHARMACOKINETICS CONCEPTS AND APPLICATIONS, (19950000), page 21, XP055635111-
OPPOSITION- R OWLAND et al., "chapter 7", CLINICAL PHARMACOKINETICS CONCEPTS AND APPLICATIONS, (19950000), pages 88 - 89, XP055635109-
OPPOSITION- Safety & Tolerability of Berinert@ (C1 Inhibitor) Therapy to Prevent D6 Rejection, (20131010), URL: https://clinicaltrials.gov/archive/NCT01134510/2013_ 10_ 10, (20150108), XP002734263-
OPPOSITION- SATOSKAR et al., "biological half-life", Pharmacology and Pharmacotherapeutics, (20090000), page 21, XP055635094-
OPPOSITION- "Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema- Safety and Efficacy of Escalating Doses Presented at the 2012 Annual Meeting of the American College of Allergy", Asthma and Immunology (ACAAI, (20121113), XP055633926-
OPPOSITION- The World Transplant Congress 2014 Abstract Supplement Extract-
OPPOSITION- VIROPHARMA, Investor presentation, (20100000), XP055635068-
OPPOSITION- TILLOU XAVIER et al., "Recombinant human C1-inhibitor prevents D10 acute antibody-mediated rejection in alloimmunized baboons", KIDNEY INTERNATIONAL, (20100700), vol. 78, no. 2, doi:10.1038/ki.2010.75, ISSN 1523-1755, pages 152 - 159, XP002734265
OPPOSITION- HEEGER, "A complementary approach to treating antibody- mediated transplant rejection", Kidney International, (20100000), vol. 78, pages 125 - 127, XP055635063
OPPOSITION- FILIPPONE et al., "Transplant glomerulopathy", Modern Pathology, (20180000), vol. 31, pages 235 - 252, XP055635114
OPPOSITION- ERIC WAGNER et al., "Therapeutic potential of complement D8 modulation", NATURE REVIEWS DRUG DISCOVERY, (20100101), vol. 9, no. 1, doi:10.1038/nrd3011, ISSN 1474-1776, pages 43 - 56, XP055085419
OPPOSITION- WAYTES, "Treatment of Hereditary Angioedema with a vapor- heated C1 inhibitor concentrate", N Engl J Med., (19960000), vol. 334, doi:10.1056/NEJM199606203342503, pages 1630 - 1634, XP055271353
OPPOSITION- CAI JUNCHAO et al., "Humoral theory of transplantation: some hot D11 topics", BRITISH MEDICAL BULLETIN, (20130000), vol. 105, doi:10.1093/bmb/lds037, ISSN 1471-8391, pages 139 - 155, XP002734266
OPPOSITION- MOHACSI et al., "The clinical relevance of antibody-mediated rejection: a new era of heart transplantation", European Journal of Cardio-Thoracic Surgery, (20120000), vol. 42, pages 1047 - 1049, XP055635128
OPPOSITION- MOHACSI et al., "Successful management of a B-type cardiac allograft into an O-type man with 3(1/2)-year clinical follow-up", Transplantation, (20010000), vol. 72, pages 1328 - 1330, XP055633918
OPPOSITION- HAAS et al., "Banff Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection And Antibody-Associated Arterial Lesions", Am J Transplant., (20140000), vol. 14, pages 272 - 283, XP055635124
OPPOSITION- MONTGOMERY et al., "Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study", American Journal of Transplantation, (20160000), vol. 16, no. 12, doi:10.1111/ajt.13871, pages 3468 - 3478, XP055583366
OPPOSITION- BERINERT, Grant/Renewal of Marketing Authorisation, Summary of Product Characteristics, (20090000), XP021132763
OPPOSITION- WALPOLE et al., "The weight of nations: an estimation of adult human biomass", BMC Public Health, (20120000), vol. 12, doi:10.1186/1471-2458-12-439, page 439, XP021132763
OPPOSITION- KATSUMA et al., "Histopathological findings in transplanted kidneys", Renal Replacement Therapy, (20170000), vol. 3, XP055635121
OPPOSITION- AKALIN et al., "Transplant glomerulopathy may occur in the absence of donor specific antibody and C4d staining", Clin J Am Soc Nephrol, (20070000), vol. 2, pages 1261 - 1267, XP055635116
OPPOSITION- HAYDE et al., "The clinical and genomic significance of donor- specific antibodypositive/C4d-negative and donor-specific antibodynegative/C4d-negative transplant glomerulopathy", Clin J Am Soc Nephrol, vol. 8, (20130900), pages 2141 - 2148, URL: https://cjasn.asnjournals.Org/content/clinjasn/early/ 2013/09/11 /CJN.042 40413.full.pdf?versioned=true, XP055635119
OPPOSITION- BHOWMIK et al., "The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians", Indian J Nephrol., (20100000), vol. 20, pages 2 - 8, XP055633938
OPPOSITION- CHRISTOPHER R. ENSOR et al., "Antibody Mediated D4 Rejection of the Cardiac Allograft", doi:10.5772/26456, (20120000), pages 23 - 40, URL: http://cdn.intechopen.com/pdfs-wm/28047.pdf, (20150108), XP002734262

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents